Mirum Pharmaceuticals, Inc. (MIRM)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 250M 500M 750M Q4 '21: 19.1M Q1 '22: 32M Q2 '22: 38.5M Q3 '22: 52.3M Q4 '22: 77.1M Q1 '23: 95.8M Q2 '23: 115.8M Q3 '23: 144.7M Q4 '23: 186.4M Q1 '24: 224M Q2 '24: 264.4M Q3 '24: 307M Q4 '24: 336.9M Q1 '25: 379.3M Q2 '25: 429.2M Q3 '25: 471.8M Q4 '25: 521.3M Q1 '26: 569.6M Q2 '26: 618.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-900M -600M -300M 0 300M 600M 900M Q3 '21: -164.8M Q4 '21: -173.4M Q1 '22: -158.5M Q2 '22: -152.6M Q3 '22: -142.6M Q4 '22: -131.2M Q1 '23: -125.6M Q2 '23: -118.5M Q3 '23: -110.7M Q4 '23: -109.2M Q1 '24: -108.5M Q2 '24: -108.4M Q3 '24: -96M Q4 '24: -87.6M Q1 '25: -76.3M Q2 '25: -57.1M Q3 '25: -41.8M Q4 '25: -22.1M Q1 '26: -796.4M Q2 '26: -834M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-900M -600M -300M 0 300M 600M 900M Q3 '21: -178.7M Q4 '21: -84M Q1 '22: -70.1M Q2 '22: -53.1M Q3 '22: -41.7M Q4 '22: -135.7M Q1 '23: -129.2M Q2 '23: -176.3M Q3 '23: -164.2M Q4 '23: -163.4M Q1 '24: -158.6M Q2 '24: -109.2M Q3 '24: -99.8M Q4 '24: -87.9M Q1 '25: -77.3M Q2 '25: -58.6M Q3 '25: -41.4M Q4 '25: -23.4M Q1 '26: -798.8M Q2 '26: -860.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-240M -160M -80M 0 80M 160M 240M Q3 '21: -135.9M Q4 '21: -132.8M Q1 '22: -147.2M Q2 '22: -127.2M Q3 '22: -119M Q4 '22: -120.1M Q1 '23: -99.2M Q2 '23: -96.4M Q3 '23: -88.6M Q4 '23: -70.9M Q1 '24: -37M Q2 '24: -23.4M Q3 '24: -1.2M Q4 '24: 10.3M Q1 '25: -6.8M Q2 '25: 9M Q3 '25: 44.7M Q4 '25: 55.8M Q1 '26: -171M Q2 '26: -227.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-240M -160M -80M 0 80M 160M 240M Q3 '21: -135.9M Q4 '21: -132.8M Q1 '22: -147.2M Q2 '22: -127.2M Q3 '22: -119.1M Q4 '22: -120.4M Q1 '23: -99.6M Q2 '23: -96.8M Q3 '23: -88.9M Q4 '23: -71.1M Q1 '24: -37M Q2 '24: -24.2M Q3 '24: -2.2M Q4 '24: 9.3M Q1 '25: -7.9M Q2 '25: 8.6M Q3 '25: 44.3M Q4 '25: 54.9M Q1 '26: -172.6M Q2 '26: -228.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 25M 50M 75M Q2 '21: 30.3M Q3 '21: 30.4M Q1 '22: 31.3M Q2 '22: 32.2M Q3 '22: 34.9M Q1 '23: 37.7M Q2 '23: 38.1M Q3 '23: 41.1M Q1 '24: 46.9M Q2 '24: 47.2M Q3 '24: 47.8M Q1 '25: 48.9M Q2 '25: 49.7M Q3 '25: 57M Q1 '26: 58.9M Q2 '26: 63.4M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-15.00 -10.00 -5.00 0.00 5.00 10.00 15.00 Q3 '21: -6.12 Q4 '21: -2.77 Q1 '22: -2.26 Q2 '22: -1.65 Q3 '22: -1.12 Q4 '22: -4.02 Q1 '23: -3.65 Q2 '23: -4.75 Q3 '23: -4.30 Q4 '23: -4.03 Q1 '24: -3.77 Q2 '24: -2.35 Q3 '24: -2.08 Q4 '24: -1.85 Q1 '25: -1.61 Q2 '25: -1.21 Q3 '25: -0.86 Q4 '25: -0.49 Q1 '26: -13.62 Q2 '26: -14.56 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.